Developer docs
API playgroundTry for free, no card

Search company profiles

American Oncology Network

Full company profile

uuid00043uz

Namestring
American Oncology Network
Legal namestring
American Oncology Network
Websiteurl
aoncology.com
Company typeenum
Public
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersFort Myers, United States
HQ citystring
Fort Myers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
community oncology network, oncology practice management, specialty pharmacy services, value-based cancer care, clinical research oncology
Industry4 codes
PRIMARYHLAFABAI
Ambulatory Oncology Centers (Outpatient Chemo/Radiation)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code3 codes
  • Offices of Physicians62111
  • Ambulatory Health Care Services621
  • All Other Outpatient Care Centers621498
SIC code3 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Health Services8000
Product category
Community Oncology Practice Management Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Practice Partnership and Management Services
TypeManaged Services
Description

AON generates revenue by partnering with independent community oncology practices, providing administrative ease, practice growth support, technology solutions, and centralized services including pathology, specialty pharmacy, and clinical trial access. Partner practices benefit from better financial outcomes while maintaining physician autonomy.

aoncology.com
2Specialty Pharmacy Services
TypeSubscription Recurring
Description

AON operates an in-house specialty pharmacy that provides oral oncolytic pharmacy services to partner practices and patients, generating revenue through prescription fulfillment and pharmacy operations.

aoncology.com
3Value-Based Care Contracts
TypeUsage Based
Description

AON participates in CMS's Enhancing Oncology Model (EOM) and other value-based care arrangements, generating revenue through quality-focused interventions and performance-based incentives.

aoncology.com
4Clinical Research and Trials
TypeProfessional Services
Description

AON generates revenue through clinical trial partnerships with organizations like Sarah Cannon Research Institute, Trial Library, and MiBA, providing access to cutting-edge research for partner practices.

aoncology.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Practice partnership model - custom pricing based on practice size and services
ModelOtherBilling cadenceMulti-year contract
Notes

AON partners with practices through a collaborative model rather than standard tiered pricing. Benefits include access to pathology, pharmacy, value-based contracting expertise, and care coordination services. Specific pricing varies by practice.

aoncology.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

American Oncology Network operates as a national network of community oncology practices, providing partner practices with centralized practice management services, in-house specialty pharmacy, pathology and laboratory diagnostics, radiation and radiology services (including radioligand therapies), value-based care program participation, care coordination, behavioral health, and clinical research access. AON enables independent oncology practices to maintain physician autonomy while accessing advanced therapies (CAR T-cell, Bispecific T-cell Engager, radioligand therapies), clinical trials, and operational infrastructure typically only available at larger healthcare systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AON posted $2B annual revenue with 40% growth in 2025
+3 more records
Product overview1 text field

American Oncology Network (AON) operates as a national network of community-based oncology practices, functioning as a platform-plus-services model. The core offering is the Practice Success Platform providing administrative ease, patient-centric care, and practice growth resources. This platform is enhanced by integrated service modules including Specialty Pharmacy, Pathology Services (with AI-enhanced karyogram segmentation via CAP-accredited Central Lab), Radiation and Radiology Services (including PET/CT and radioligand therapies), Value-Based Care programs (participating in CMS's Enhancing Oncology Model), and Care Coordination. AON has expanded into advanced immunotherapies including Bispecific T-cell Engager (BiTE) therapies at 40+ clinics and outpatient CAR T-cell therapy programs. The network also integrates behavioral health support through Colla Health partnerships and emotional peer support via CanCare. Research capabilities are powered through American Oncology Research with partnerships enabling AI-driven clinical trial matching (Trial Library), real-time data intelligence (MiBA), and traditional research collaborations (Sarah Cannon Research Institute). The network spans 21 states with over 350 providers and $2B in annual revenue.

Product and service12 records
1Practice Success Platform
CategoryOncology Practice Management
Description

Comprehensive partnership platform supporting community oncology practices with patient-centric care, administrative ease, practice growth, value-based care participation (CMS Enhancing Oncology Model), and operational resources.

2Specialty Pharmacy Services
3Pathology Services
4Radiation and Radiology Services
5Value-Based Care Program
6Care Coordination
7CanCare Peer Support Program
CategoryPatient Support Services
Description

Partnership with CanCare providing free emotional peer support connecting cancer patients with trained volunteer survivors and caregivers matched by diagnosis or experience, delivered via phone, email, text, or in person.

8Colla Health Behavioral Health Services
CategoryBehavioral Health Services
Description

Partnership with Colla Health providing personalized behavioral health support through telehealth and phone services, including therapeutic interventions and psychiatric oversight for cancer patients.

9Clinical Research (American Oncology Research)
10Bispecific T-cell Engager (BiTE) Therapies
CategoryAdvanced Immunotherapy
Description

Administration of bispecific antibody therapies in outpatient community oncology settings across 40+ clinics, with standardized protocols, staff training, and patient education materials for at-home monitoring.

11Outpatient CAR T-cell Therapy Program
CategoryAdvanced Immunotherapy
Description

FDA-approved CAR T-cell therapy administration in outpatient community oncology settings, enabling advanced immunotherapy access closer to patients' homes; The Center for Cancer and Blood Disorders became one of the first community oncology practices in the U.S. to offer CAR T-cell therapy outside a hospital setting.

12Radioligand Therapies
CategoryRadiopharmaceutical Therapy
Description

Advanced radiopharmaceutical treatments including Pluvicto (metastatic prostate cancer), Lutathera (neuroendocrine tumors), and Xofigo (bone metastases), offering targeted radiation delivery. Over 300 treatments delivered to nearly 70 patients across six partner practices.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Partnership to provide whole-person cancer care combining advanced medical treatment with emotional peer support from trained cancer survivors and caregivers. CanCare volunteers are matched with patients based on diagnosis or life experience and provide support by phone, email, text, or in person. The partnership builds on successful pilot programs at four AON partner practices and will expand nationwide.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Partnership to expand behavioral health services for cancer patients in community oncology settings. The collaboration addresses emotional and psychological challenges accompanying cancer diagnosis, treatment, and survivorship through telehealth and phone-based services. Launches with two AON partner practices and expands to all practices nationwide by end of 2026.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Zangmeister Cancer Center became an affiliate of The Ohio State University Comprehensive Cancer Center through The James Cancer Network. The affiliation increases clinical trial availability and access to advanced therapies including CAR T-cell therapy and proton therapy for central Ohio patients.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-15
Description

Strategic alliance to integrate AI-enhanced data intelligence into community oncology clinical research. The alliance embeds real-time data workflows to reduce timelines between site selection and patient enrollment while improving trial accessibility and helping meet Diversity Action Plan requirements through data-driven inclusive enrollment strategies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Innovative partnership model to improve cancer care while eliminating prior authorization burden. The collaboration introduces quality-focused interventions, drives clinical insights through data and analytics platform, and rewards providers for high-quality care.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Collaboration developing data-driven, patient-centered, value-based oncology care. Presented nine research abstracts at ASCO Quality 2025 focusing on improving care models, policy implications, patient outcomes, and health equity based on real-world data from AON's clinical network.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-13
Description

Partnership to expand patient access to cancer clinical trials as a care option. Trial Library uses AI-enabled platform for clinical trial matching and patient navigation. The partnership integrates clinical research into standard care delivery across AON's network of 320+ clinics and 1,500+ providers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

Partnership to improve cancer patient outcomes with AI-enabled value-based care platform. Collaboration focuses on enhancing cancer care delivery through data-driven insights and value-based care optimization.

9Sarah Cannon Research Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-15
Description

Cancer research collaboration expanding patient access to community-based clinical trials. AON and Sarah Cannon offer clinical trial options to patients across several locations within AON's network, with strategic research sites including Hematology Oncology Clinic and Messino Cancer Centers.

aoncology.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-05-28
Description

Master contract for THOR light therapy scalp cooling technology. The Center for Cancer and Blood Disorders became the first medical oncology network in the United States to offer THOR light therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-06
Description

Continuing strategic relationship with global healthcare solutions leader AmerisourceBergen for pharmaceutical distribution and supply chain services.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private equity-backed national network of independent community oncology practices, founded by former US Oncology executives. Direct competitor to AON in aggregating independent oncology practices and providing practice management, pharmacy, and value-based care services.

2The US Oncology Network
TypeDirect peer
Description

Subsidiary of McKesson; one of the largest community oncology networks in the US, providing practice management, technology, and clinical research support to independent oncology practices. AON's primary direct competitor and a target competitor for practice affiliation.

TypeDirect peer
Description

Large independent community oncology and hematology practice in Florida with significant clinical research operations. Comparable as a high-volume community oncology provider offering advanced therapies and clinical trials outside academic centers.

TypeDirect peer
Description

One of the largest community-based oncology practices in the US, affiliated with US Oncology Network. Operates a multi-state network of community oncology clinics with advanced therapy offerings comparable to AON's footprint.

TypeDirect peer
Description

Large independent community oncology practice serving Tennessee and surrounding states, including OneOncology-affiliated sites. Comparable to AON in scale, advanced therapy delivery, and clinical research integration in community settings.

6Sarah Cannon Research Institute
TypeBroad incumbent
Description

Cancer research institute within HCA Healthcare that partners with community oncology networks (including AON) for clinical trial delivery. Adjacent rather than direct competitor, but a critical ecosystem player for community-based oncology research.

7McKesson
TypeBroad incumbent
Description

Parent of The US Oncology Network and a major pharmaceutical distributor (including AmerisourceBergen, an AON partner). As the incumbent aggregator in community oncology, McKesson is both a competitor (via US Oncology) and a strategic partner/distributor to AON.

TypeEmerging player
Description

Value-based cancer care enabler partnering with AON and community oncology networks to deliver oncology navigation, care management, and risk-bearing arrangements with payers. Comparable in the value-based oncology services layer where AON is positioning.

TypeEmerging player
Description

Emerging risk-bearing primary and specialty care enablement company expanding into oncology value-based arrangements. Represents the broader shift toward risk-bearing care models that affect AON's specialty positioning.

TypeBroad incumbent
Description

Major NCI-designated academic cancer center expanding community oncology affiliations (including acquisitions of community oncology groups in California). Represents the incumbent academic-system expansion that competes with AON for advanced therapy referrals and physician talent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

American Oncology Network

Community Oncology Practice Management Servicesaoncology.com

American Oncology Network firmographics

Firmographics
Name
American Oncology Network
Legal name
American Oncology Network
Website
https://aoncology.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

American Oncology Network industry classification

Industry
Product category
Community Oncology Practice Management Services
NAICS
Offices of Physicians (62111), Ambulatory Health Care Services (621), All Other Outpatient Care Centers (621498)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAFABAI
Ambulatory Oncology Centers (Outpatient Chemo/Radiation)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Community oncology network
  • Oncology practice management
  • Specialty pharmacy services
  • Value-based cancer care
  • Clinical research oncology

Where American Oncology Network is headquartered

Location

Headquarters

HQ city
Fort Myers
HQ country
United States
HQ region
North America

Offices1 record

Markets served

American Oncology Network business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Practice Partnership and Management Services: AON generates revenue by partnering with independent community oncology practices, providing administrative ease, practice growth support, technology solutions, and centralized services including pathology, specialty pharmacy, and clinical trial access. Partner practices benefit from better financial outcomes while maintaining physician autonomy.
  2. Specialty Pharmacy Services: AON operates an in-house specialty pharmacy that provides oral oncolytic pharmacy services to partner practices and patients, generating revenue through prescription fulfillment and pharmacy operations.
  3. Value-Based Care Contracts: AON participates in CMS's Enhancing Oncology Model (EOM) and other value-based care arrangements, generating revenue through quality-focused interventions and performance-based incentives.
  4. Clinical Research and Trials: AON generates revenue through clinical trial partnerships with organizations like Sarah Cannon Research Institute, Trial Library, and MiBA, providing access to cutting-edge research for partner practices.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPractice partnership model - custom pricing based on practice size and services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

American Oncology Network product offering

Product offering

Core offering

American Oncology Network operates as a national network of community oncology practices, providing partner practices with centralized practice management services, in-house specialty pharmacy, pathology and laboratory diagnostics, radiation and radiology services (including radioligand therapies), value-based care program participation, care coordination, behavioral health, and clinical research access. AON enables independent oncology practices to maintain physician autonomy while accessing advanced therapies (CAR T-cell, Bispecific T-cell Engager, radioligand therapies), clinical trials, and operational infrastructure typically only available at larger healthcare systems.

Product overview

American Oncology Network (AON) operates as a national network of community-based oncology practices, functioning as a platform-plus-services model. The core offering is the Practice Success Platform providing administrative ease, patient-centric care, and practice growth resources. This platform is enhanced by integrated service modules including Specialty Pharmacy, Pathology Services (with AI-enhanced karyogram segmentation via CAP-accredited Central Lab), Radiation and Radiology Services (including PET/CT and radioligand therapies), Value-Based Care programs (participating in CMS's Enhancing Oncology Model), and Care Coordination. AON has expanded into advanced immunotherapies including Bispecific T-cell Engager (BiTE) therapies at 40+ clinics and outpatient CAR T-cell therapy programs. The network also integrates behavioral health support through Colla Health partnerships and emotional peer support via CanCare. Research capabilities are powered through American Oncology Research with partnerships enabling AI-driven clinical trial matching (Trial Library), real-time data intelligence (MiBA), and traditional research collaborations (Sarah Cannon Research Institute). The network spans 21 states with over 350 providers and $2B in annual revenue.

Differentiator

Problem solved

Functional benefit

Products and services

  • Practice Success Platform Comprehensive partnership platform supporting community oncology practices with patient-centric care, administrative ease, practice growth, value-based care participation (CMS Enhancing Oncology Model), and operational resources.
  • Specialty Pharmacy Services
  • Pathology Services
  • Radiation and Radiology Services
  • Value-Based Care Program
  • Care Coordination
  • CanCare Peer Support Program Partnership with CanCare providing free emotional peer support connecting cancer patients with trained volunteer survivors and caregivers matched by diagnosis or experience, delivered via phone, email, text, or in person.
  • Colla Health Behavioral Health Services Partnership with Colla Health providing personalized behavioral health support through telehealth and phone services, including therapeutic interventions and psychiatric oversight for cancer patients.
  • Clinical Research (American Oncology Research)
  • Bispecific T-cell Engager (BiTE) Therapies Administration of bispecific antibody therapies in outpatient community oncology settings across 40+ clinics, with standardized protocols, staff training, and patient education materials for at-home monitoring.
  • Outpatient CAR T-cell Therapy Program FDA-approved CAR T-cell therapy administration in outpatient community oncology settings, enabling advanced immunotherapy access closer to patients' homes; The Center for Cancer and Blood Disorders became one of the first community oncology practices in the U.S. to offer CAR T-cell therapy outside a hospital setting.
  • Radioligand Therapies Advanced radiopharmaceutical treatments including Pluvicto (metastatic prostate cancer), Lutathera (neuroendocrine tumors), and Xofigo (bone metastases), offering targeted radiation delivery. Over 300 treatments delivered to nearly 70 patients across six partner practices.

Quantifiable outcome

  • AON posted $2B annual revenue with 40% growth in 2025
  • +3 more outcomes

Companies that use American Oncology Network

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles1 record

American Oncology Network technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability7 records

Feature4 records

American Oncology Network partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

  • CanCare, Inc.coreStrategic or Co-development Partner · 11 June 2026Partnership to provide whole-person cancer care combining advanced medical treatment with emotional peer support from trained cancer survivors and caregivers. CanCare volunteers are matched with patients based on diagnosis or life experience and provide support by phone, email, text, or in person. The partnership builds on successful pilot programs at four AON partner practices and will expand nationwide.
  • Colla HealthcoreStrategic or Co-development Partner · 10 June 2026Partnership to expand behavioral health services for cancer patients in community oncology settings. The collaboration addresses emotional and psychological challenges accompanying cancer diagnosis, treatment, and survivorship through telehealth and phone-based services. Launches with two AON partner practices and expands to all practices nationwide by end of 2026.
  • The Ohio State University Comprehensive Cancer Center – James Cancer HospitalflagshipStrategic or Co-development Partner · 21 May 2026Zangmeister Cancer Center became an affiliate of The Ohio State University Comprehensive Cancer Center through The James Cancer Network. The affiliation increases clinical trial availability and access to advanced therapies including CAR T-cell therapy and proton therapy for central Ohio patients.
  • MiBA (Meaningful Insights Biotech Analytics)coreTechnology or Integration · 15 January 2026Strategic alliance to integrate AI-enhanced data intelligence into community oncology clinical research. The alliance embeds real-time data workflows to reduce timelines between site selection and patient enrollment while improving trial accessibility and helping meet Diversity Action Plan requirements through data-driven inclusive enrollment strategies.
  • Evolent HealthcoreStrategic or Co-development Partner · 6 November 2025Innovative partnership model to improve cancer care while eliminating prior authorization burden. The collaboration introduces quality-focused interventions, drives clinical insights through data and analytics platform, and rewards providers for high-quality care.
  • Thyme CarecoreStrategic or Co-development Partner · 10 October 2025Collaboration developing data-driven, patient-centered, value-based oncology care. Presented nine research abstracts at ASCO Quality 2025 focusing on improving care models, policy implications, patient outcomes, and health equity based on real-world data from AON's clinical network.
  • Trial LibrarycoreStrategic or Co-development Partner · 13 March 2025Partnership to expand patient access to cancer clinical trials as a care option. Trial Library uses AI-enabled platform for clinical trial matching and patient navigation. The partnership integrates clinical research into standard care delivery across AON's network of 320+ clinics and 1,500+ providers.
  • Vantage Health TechnologiescoreTechnology or Integration · 29 October 2024Partnership to improve cancer patient outcomes with AI-enabled value-based care platform. Collaboration focuses on enhancing cancer care delivery through data-driven insights and value-based care optimization.
  • Sarah Cannon Research InstitutecoreStrategic or Co-development Partner · 15 June 2020Cancer research collaboration expanding patient access to community-based clinical trials. AON and Sarah Cannon offer clinical trial options to patients across several locations within AON's network, with strategic research sites including Hematology Oncology Clinic and Messino Cancer Centers.
  • Dignitana ABminorGTM or Marketing Partner · 28 May 2020Master contract for THOR light therapy scalp cooling technology. The Center for Cancer and Blood Disorders became the first medical oncology network in the United States to offer THOR light therapy.
  • AmerisourceBergencoreStrategic or Co-development Partner · 6 March 2020Continuing strategic relationship with global healthcare solutions leader AmerisourceBergen for pharmaceutical distribution and supply chain services.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

American Oncology Network competitors and assessment

Company assessment

Direct peers

  • OneOncology: Private equity-backed national network of independent community oncology practices, founded by former US Oncology executives. Direct competitor to AON in aggregating independent oncology practices and providing practice management, pharmacy, and value-based care services.
  • The US Oncology Network: Subsidiary of McKesson; one of the largest community oncology networks in the US, providing practice management, technology, and clinical research support to independent oncology practices. AON's primary direct competitor and a target competitor for practice affiliation.
  • Florida Cancer Specialists & Research Institute: Large independent community oncology and hematology practice in Florida with significant clinical research operations. Comparable as a high-volume community oncology provider offering advanced therapies and clinical trials outside academic centers.
  • Texas Oncology: One of the largest community-based oncology practices in the US, affiliated with US Oncology Network. Operates a multi-state network of community oncology clinics with advanced therapy offerings comparable to AON's footprint.
  • Tennessee Oncology / Astera Cancer Care: Large independent community oncology practice serving Tennessee and surrounding states, including OneOncology-affiliated sites. Comparable to AON in scale, advanced therapy delivery, and clinical research integration in community settings.

Broad incumbents

  • Sarah Cannon Research Institute: Cancer research institute within HCA Healthcare that partners with community oncology networks (including AON) for clinical trial delivery. Adjacent rather than direct competitor, but a critical ecosystem player for community-based oncology research.
  • McKesson: Parent of The US Oncology Network and a major pharmaceutical distributor (including AmerisourceBergen, an AON partner). As the incumbent aggregator in community oncology, McKesson is both a competitor (via US Oncology) and a strategic partner/distributor to AON.
  • City of Hope: Major NCI-designated academic cancer center expanding community oncology affiliations (including acquisitions of community oncology groups in California). Represents the incumbent academic-system expansion that competes with AON for advanced therapy referrals and physician talent.

Emerging players

  • Thyme Care: Value-based cancer care enabler partnering with AON and community oncology networks to deliver oncology navigation, care management, and risk-bearing arrangements with payers. Comparable in the value-based oncology services layer where AON is positioning.
  • Pearl Health: Emerging risk-bearing primary and specialty care enablement company expanding into oncology value-based arrangements. Represents the broader shift toward risk-bearing care models that affect AON's specialty positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

American Oncology Network social profiles

Digital presence

American Oncology Network compliance and trust

Trust signal

Compliance4 records

American Oncology Network financial estimates

Financial estimate

Revenue estimate

Valuation estimate

American Oncology Network leadership team

Management profile

Number of profiles

Profiles14 records

American Oncology Network subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

American Oncology Network funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

American Oncology Network M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Oncology Network

What does American Oncology Network do?

American Oncology Network operates as a national network of community oncology practices, providing partner practices with centralized practice management services, in-house specialty pharmacy, pathology and laboratory diagnostics, radiation and radiology services (including radioligand therapies), value-based care program participation, care coordination, behavioral health, and clinical research access. AON enables independent oncology practices to maintain physician autonomy while accessing advanced therapies (CAR T-cell, Bispecific T-cell Engager, radioligand therapies), clinical trials, and operational infrastructure typically only available at larger healthcare systems.

Is American Oncology Network a public or private company?

American Oncology Network is a public company. It is classified as public and is currently operating.

When was American Oncology Network founded?

American Oncology Network was founded in 2018. It employs 501 to 1,000 people.

Where is American Oncology Network based?

American Oncology Network is headquartered in Fort Myers, United States, in the North America region.

How does American Oncology Network make money?

Four revenue lines are on record. Practice Partnership and Management Services are the primary driver. The others are specialty Pharmacy Services, value-Based Care Contracts and clinical Research and Trials.

Who are American Oncology Network's main competitors?

Direct peers on record are OneOncology, The US Oncology Network, Florida Cancer Specialists & Research Institute, Texas Oncology and Tennessee Oncology / Astera Cancer Care. Broad incumbents are Sarah Cannon Research Institute, McKesson and City of Hope. Emerging players are Thyme Care and Pearl Health.

Does American Oncology Network have an API?

No public API is recorded for American Oncology Network.

What industry is American Oncology Network in?

American Oncology Network's product category is Community Oncology Practice Management Services. Its primary akta.pro industry code is HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation), with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 62111 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCan HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?Humana launched a new oncology model with Evolent and American Oncology Network across eight states, allowing adhering practices to bypass prior authorization for most anticancer drugs. The model uses data analytics and provider education to encourage evidence-based treatment. It extends Humana's value-based care into specialty treatments.BenzingaWhy Is Humana Stock Trading Higher Tuesday? - Humana (NYSE:HUM)Humana's stock rose over 3% on Tuesday after the insurer announced a new cancer care model with Evolent Health and American Oncology Network across eight states. The company also raised its 2026 adjusted earnings forecast to at least $9.50 per share, following a Q3 loss of 70 cents per share. Analysts raised price targets, with JPMorgan maintaining a Neutral rating.Business Wire BlogNew oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burdenHumana, Evolent, and American Oncology Network launched a new cancer care model across eight states that eliminates prior authorization for most anticancer drug therapies. The model uses quality improvement initiatives and a data-driven analytics platform to streamline care. It builds on a 20-year partnership between Humana and Evolent.Stock TitanEvolent and Humana launch cancer care model in 8 statesHumana, Evolent, and American Oncology Network launched a cancer care model in eight states that reduces prior authorization for anticancer drugs. The model streamlines therapy management and uses quality improvement initiatives, building on a 20-year partnership.Investing.comCencora earnings ahead: Margin expansion in focus amid slowdownCencora will report fiscal Q4 earnings Wednesday, with analysts expecting EPS of $4.57 on revenue of $87.97 billion. The company is projected to grow earnings 19% year-over-year and revenue 5.1%, reflecting margin improvement amid industry slowdown. The acquisition of American Oncology Network for up to $2.4 billion will be a key discussion point.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC)Brodsky & Smith notified investors of four merger investigations: Lumentum, Surgery Partners, Range Resources, and American Oncology Network. The deals involve Marvell, HealthSpan, EQT, and Cencora, with enterprise values of $115B, $5.7B, $50B, and $2.4B respectively. The firm alleges breach of fiduciary duties and failure to conduct a fair process.YahooIs Cencora (COR) Fully Valued Following Its $2.4b American Oncology Network Deal?Cencora agreed to buy American Oncology Network in a deal valued at up to $2.4 billion, reshaping its community cancer care footprint. The stock trades near $330.84, with a fair value estimate of $369, implying about 10% undervaluation. The company also has $1 billion in completed share repurchases and $2 billion authorized.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, InBrodsky & Smith notified investors of four merger investigations: Surgery Partners, Range Resources, American Oncology Network, and Utz Brands. The deals involve cash or stock acquisitions with enterprise values ranging from $2.4 billion to over $50 billion, and the investigations question whether boards breached fiduciary duties by failing to conduct fair processes.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)Brodsky & Smith notified investors of investigations into four merger deals: Surgery Partners, Range Resources, American Oncology Network, and Utz Brands. The deals involve cash or stock acquisitions with enterprise values ranging from $2.4 billion to over $50 billion, and the investigations question whether boards breached fiduciary duties by failing to conduct fair processes.Pulse 2.0Cencora To Acquire American Oncology Network In $2.4 Billion DealCencora signed a definitive agreement to acquire American Oncology Network for approximately $2.4 billion, expanding its physician-led oncology management services. The deal includes contingent value rights up to $100 million and is expected to be accretive to adjusted diluted EPS in the second year after closing.